Rabogenix-DSR

Rabogenix-DSR is a fixed-dose combination pharmaceutical product developed and marketed by Nilegenix, a generic pharmaceutical company based in India. It contains two active ingredients: rabeprazole, a proton pump inhibitor (PPI), and domperidone, a dopamine antagonist with prokinetic and anti-emetic properties. Rabeprazole works by inhibiting the H+/K+-ATPase enzyme system (the proton pump) in gastric parietal cells, which effectively reduces gastric acid secretion. Domperidone acts as a peripheral dopamine D2 receptor antagonist, which increases gastrointestinal motility and lower esophageal sphincter pressure while suppressing nausea and vomiting by acting on the chemoreceptor trigger zone. This combination is primarily indicated for the treatment of gastroesophageal reflux disease (GERD), acid reflux, and associated symptoms such as nausea and dyspepsia. The "DSR" designation typically indicates a sustained-release formulation of domperidone combined with rabeprazole.

Brand names

Rabogenix-DSR

Other names

rabeprazole + domperidone